Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

References

• Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primer. 2017;3(1):17028, doi:10.1038/nrdp.2017.28
   PubMedGoogle Scholar
• Socié G, Mary JY, De Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348(9027):573–577. doi:10.1016/S0140-6736(95)12360-1
   PubMed Web of Science ®Google Scholar
• Socié G, Schrezenmeier H, Muus P, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry: Paroxysmal nocturnal haemoglobinuria. Intern Med J. 2016;46(9):1044–1053. doi:10.1111/imj.13160
   PubMed Web of Science ®Google Scholar
• Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(10):1304–1309. doi:10.1182/blood.2019003812
   PubMed Web of Science ®Google Scholar
• Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther. 2020;20(3):227–237. doi:10.1080/14712598.2020.1725468
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786–6792. doi:10.1182/blood-2011-02-333997
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Röth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73. doi:10.1111/bjh.12347
   PubMed Web of Science ®Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. doi:10.1056/NEJMoa2029073
   PubMed Web of Science ®Google Scholar
• Wong RSM. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2022;13:1–17. doi:10.1177/20406207221114673
   Web of Science ®Google Scholar
• Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95(11):1334–1343. doi:10.1002/ajh.25960
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157, doi:10.3389/fimmu.2019.01157
   PubMed Web of Science ®Google Scholar
• Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. Longo DL, ed. N Engl J Med. 2022;387(2):160–166. doi:10.1056/NEJMra2201664
   PubMed Web of Science ®Google Scholar
• Brodsky RA, De Latour RP, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2020;106(1):230–237. doi:10.3324/haematol.2019.236877
   Web of Science ®Google Scholar
• Risitano AM, Han B, Ueda Y, et al. OS12-06 oral complement factor B inhibitor Iptacopan monotherapy improves hemoglobin to normal/near-normal levels in paroxysmal nocturnal hemoglobinuria patients naïve to complement inhibitors: phase III APPOINT-PNH trial. Presented at: 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT); April 23, 2023; Paris, France. Accessed October 2, 2023. https://clin.larvol.com/abstract-detail/EBMT%202023/63248157.
   Google Scholar
• de Latour RP, Roeth A, Kulasekararaj A, et al. Oral monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study. Blood. 2022;140(Supplement LBA-2): doi:10.1182/blood-2022-171469
   Google Scholar
• Kulasekararaj AG, Griffin M, Langemeijer S, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. Eur J Haematol. 2022;109(3):205–214. doi:10.1111/ejh.13783
   PubMed Web of Science ®Google Scholar
• Risitano AM, Kulasekararaj AG, Lee JW, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2020;106(12):3188–3197. doi:10.3324/haematol.2020.261826
   Web of Science ®Google Scholar
• Gerber GF, Brodsky RA. Pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Blood. 2022;139(23):3361–3365. doi:10.1182/blood.2021014868
   PubMed Web of Science ®Google Scholar
• Pegcetacoplan versus Eculizumab in PNH. N Engl J Med. 2021;385(18):1723–1726. doi:10.1056/NEJMc2106424
   PubMed Web of Science ®Google Scholar
• Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102(10):3587–3591. doi:10.1182/blood-2003-02-0593
   PubMed Web of Science ®Google Scholar
• Röth A, Hock C, Konik A, et al. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol. 2011;93(6):704–714. doi:10.1007/s12185-011-0867-y
   PubMed Web of Science ®Google Scholar
• Sica M, Rondelli T, Ricci P, et al. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes. J Hematol OncolJ Hematol Oncol. 2017;10(1):126, doi:10.1186/s13045-017-0496-x
   PubMedGoogle Scholar
• Risitano AM, Peffault De Latour R, Marano L, et al. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls. Semin Immunol. 2022;59:101618, doi:10.1016/j.smim.2022.101618
   PubMed Web of Science ®Google Scholar
• Bodó I, Amine I, Boban A, et al. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): a systematic review and expert opinion from Central Europe on special patient populations. Adv Ther. 2023;40(6):2752–2772. doi:10.1007/s12325-023-02510-4
   PubMed Web of Science ®Google Scholar
• Risitano AM, Peffault De Latour R. How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol. 2022;196(2):288–303. doi:10.1111/bjh.17753
   PubMed Web of Science ®Google Scholar
• Schubert J, Bettelheim P, Brümmendorf TH, et al. Paroxysmale Nächtliche Hämoglobinurie (PNH) [Paroxysmal Nocturnal Hemoglobinuria (PNH)]. Onkopedia. Published June 2023. Accessed August 25, 2023. https://www.onkopedia.com/de/onkopedia/guidelines/paroxysmale-naechtliche-haemoglobinurie-pnh.
   Google Scholar
• Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979–983. doi:10.2105/AJPH.74.9.979
   PubMed Web of Science ®Google Scholar
• Bickel KE, McNiff K, Buss MK, et al. Defining high-quality palliative care in oncology practice: An American society of clinical oncology/American academy of hospice and palliative medicine guidance statement. J Oncol Pract. 2016;12(9):e828–e838. doi:10.1200/JOP.2016.010686
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Fisher GA, Benson AB, et al. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified Delphi process. Pancreas. 2013;42(3):397–404. doi:10.1097/MPA.0b013e31826d3a17
   PubMed Web of Science ®Google Scholar
• Geer EB, Ayala A, Bonert V, et al. Follow-up intervals in patients with Cushing’s disease: recommendations from a panel of experienced pituitary clinicians. Pituitary. 2017;20(4):422–429. doi:10.1007/s11102-017-0801-2
   PubMed Web of Science ®Google Scholar
• Herman PM, Hurwitz EL, Shekelle PG, et al. Clinical scenarios for which spinal mobilization and manipulation are considered by an expert panel to be inappropriate (and appropriate) for patients with chronic low back pain. Med Care. 2019;57(5):391–398. doi:10.1097/MLR.0000000000001108
   PubMed Web of Science ®Google Scholar
• Cuker A, Despotovic JM, Grace RF, et al. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost. 2021;5(1):69–80. doi:10.1002/rth2.12457.
   PubMed Web of Science ®Google Scholar
• Hemingway H, Crook AM, Dawson JR, et al. Rating the appropriateness of coronary angiography, coronary angioplasty and coronary artery bypass grafting: the ACRE study. Appropriateness of Coronary Revascularisation Study. J Public Health Med. 1999;21(4):421–429. doi:10.1093/pubmed/21.4.421
   PubMedGoogle Scholar
• Campbell SM. Research methods used in developing and applying quality indicators in primary care. Qual Saf Health Care. 2002;11(4):358–364. doi:10.1136/qhc.11.4.358
   PubMed Web of Science ®Google Scholar
• Fitch K, ed. The rand/UCLA appropriateness method user’s manual. Rand: Publi; 2001.
   Google Scholar
• Debureaux PE, Kulasekararaj AG, Cacace F, et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 2021;56(10):2600–2602. doi:10.1038/s41409-021-01372-0
   PubMed Web of Science ®Google Scholar
• Hemingway H, Crook AM, Feder G, et al. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med. 2001;344(9):645–654. doi:10.1056/NEJM200103013440906
   PubMed Web of Science ®Google Scholar
• Kravitz RL, Laouri M, Kahan JP, et al. Validity of criteria used for detecting underuse of coronary revascularization. JAMA. 1995;274(8):632–638. doi:10.1001/jama.1995.03530080048040
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor Eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847. doi:10.1182/blood-2007-06-094136
   PubMed Web of Science ®Google Scholar
• Apellis Pharmaceuticals, Inc. EMPAVELI® (pegcetacoplan) injection, for subcutaneous use [Prescribing information]. Published online September 2023.
   Google Scholar
• Griffin M, Kelly R, Deeren D, et al. Intensive pegcetacoplan dosing in the management of acute hemolysis as part of the 307 open-label extension study. Blood. 2022;140(Supplement 1):2937–2939. doi:10.1182/blood-2022-163117
   Google Scholar
• Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood. 1982;60(1):20–23. doi:10.1182/blood.V60.1.20.20
   PubMed Web of Science ®Google Scholar
• Röth A, Alashkar F, Herich-Terhürne D, et al. Paroxysmal nocturnal haemoglobinuria: to prednisone or not to prednisone? – A case report of a patient previously treated with steroids for 15 yrs and significant response on eculizumab. Eur J Haematol. 2015;95(2):177–180. doi:10.1111/ejh.12480
   PubMed Web of Science ®Google Scholar
• Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology. 2016;2016(1):208–216. doi:10.1182/asheducation-2016.1.208
   PubMedGoogle Scholar
• Shekelle PG, Kahan JP, Bernstein SJ, et al. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med. 1998;338(26):1888–1895. doi:10.1056/NEJM199806253382607
   PubMed Web of Science ®Google Scholar
• Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA. 2016;316(19):2025, doi:10.1001/jama.2016.9185
   PubMed Web of Science ®Google Scholar